Flagship Pioneering, a bioplatform innovation company, and Samsung, have partnered to foster biopharmaceutical innovation through advancements in translational science and medicine.

Samsung will work alongside Flagship-founded companies leveraging its technologies and capabilities to accelerate first and best-in-class therapies. The strategic partnership expands upon an ongoing cooperation between Samsung and Flagship and leverages the expertise of both organizations in the areas of life science technology, artificial intelligence, and contract development and manufacturing (CDMO) services, and extends across Flagship’s ecosystem of companies.

The collaboration will leverage artificial intelligence, translational medicine, access to high quality clinical samples and Samsung’s clinical trials infrastructure, and investment by Samsung in Flagship-founded companies.

“This collaboration represents a significant milestone in the pursuit of innovation and scientific excellence,” said Stephen Berenson, managing partner, Flagship Pioneering. “As partners, we will bring together Flagship Pioneering’s unparalleled expertise in inventing and developing revolutionary bioplatform companies with Samsung’s strategic capabilities to reshape and empower the bio-pharmaceutical landscape, ultimately resulting in bigger leaps for patient care.”

Jaywoo Kim, executive vice president, Samsung C&T said, “This newly formed collaboration is an important evolution of the ongoing relationship between two companies. We look forward to seeing the accelerating effect of Samsung’s various technical expertise and extensive commercial capabilities on the future innovations Flagship and its ecosystem of companies will bring to market.”